Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...

Discontinuing obesity medicines often means the weight comes back and people lose the cardiovascular and metabolic benefits ...

Changes are coming in 2026 for GLP-1 drugs. Long defined by high prices, shortages and weekly injections, drugs including ...

The treatment also prevented the development of arthritis after knee injuries such as ACL tears often experienced by athletes ...

Given that HCV is a bloodborne virus, any circumstance that promotes continued drug injection—including failure to prevent or diagnose and adequately treat substance use disorders—can result in ...

Health system pharmacists and clinicians are monitoring a wave of drug approvals expected throughout 2026, including first-in-class therapies and expanded uses of existing drugs with implications for ...